105 Diagnostic utility of molecular and imaging biomarkers 2 other inclusion & exclusion criteria FNAC sample BRAFV600E / BRAFK601E molecular technique TN n.o.s. air-dried FNAC smears n.s. PCR and pyrosequencing TN; histological f/u available FNAC needle washout BRAFV600E AS-PCR and direct sequencing TN; additional representative FNAC slide available for BRAF mutation analysis archived FNAC slides BRAFV600E real-time LightCycler PCR and FMCA TN; sufficient DNA quality and quantity FNAC needle washout BRAFV600E pyrosequencing for BRAF TN; sufficient nucleic acids for molecular analysis; histological f/u available residual material from two FNAC passes BRAFV600E +BRAFK601E ThyroSeq® v2 TN; ≥2 FNAC slides with sufficient cells available; histological f/u available archived FNAC slides BRAFV600E PCR and pyrosequencing TN; ≥2 FNAC slides with sufficient cells available FNAC slide BRAFV600E Roche Cobas™ Mutation Test TN without suspicious US characteristics; f/u available FNAC needle washout BRAFV600E Taqman multiplex real-time PCR TN n.o.s. FNAC needle washout BRAFV600E PCR, sanger sequencing, HRM analysis TN; second FNAC performed for BRAF mutation analysis; histological f/u available fresh FNAC samples BRAFV600E +BRAFK601E PCR, anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR MoAb) and pyrosequencing TN; size >1cm; histological f/u available air-dried FNAC smears BRAFV600E +BRAFK601E Real-time PCR, HRM and pyrosequencing adults; TN; no history of radiation exposure; no family history of thyroid carcinoma; histological f/u available FNAC cell block BRAFV600E PCR and pyrosequencing adult with solitary cold TN ≥10mm; suspicious on US; normal TSH and calcitonin; histologic f/u available representative archived FNAC slide BRAFV600E direct sequencing TN; histological f/u available if BRAF/RAS mutation detected or size >2cm or suspicious US features or resection upon patient request FNAC slides BRAFV600E +BRAFK601E PCR and pyrosequencing TN; histological f/u available pre-operative FNAC samples BRAFV600E PCR and direct sequencing; DPO-based AS-PCR; MEMO-based real-time RT-PCR TN n.o.s. FNAC needle washout BRAFV600E +BRAFK601E HRM and internal control by pyrosequencing in several samples TN; sufficient DNA for molecular analysis; histological f/u available cell blocks, or FNAC smears if DNA from cell block <10 ng BRAFV600E +BRAFK601E AmpliSeq™ Cancer Hotspot Panel v2 TN n.o.s. residual material from 1 or 2 FNAC passes BRAFV600E +BRAFK601E ThyroSeq® v2.1 TN; suspicious US features; histological or clinical f/u available residual material from FNAC BRAFV600E Real-Q BRAF Detection Assay versus AS-PCR; discordant results confirmed by MEMO sequencing TN; suspicious US features; histological or cytological f/u available additional needle pass BRAFV600E PCR and direct sequencing TN; suspicious US features; histological f/u available liquid based FNAC BRAFV600E real-time RT-PCR TN; histological or clinical f/u available residual material from FNAC BRAFV600E Sanger sequencing, AS-PCR and qPCR TN n.o.s. n.s. BRAFV600E miRinform® Thyroid Test
RkJQdWJsaXNoZXIy MTk4NDMw